EFFECTS OF THE BETA-2-ADRENERGIC AGONIST ZINTEROL ON DRL BEHAVIOR AND LOCOMOTOR-ACTIVITY

被引:15
作者
ODONNELL, JM
机构
[1] Department of Pharmacology and Therapeutics, Louisiana State University Medical School, Shreveport, 71130, LA
关键词
ANTIDEPRESSANT DRUGS; BETA ADRENERGIC RECEPTORS; LOCOMOTOR ACTIVITY; OPERANT BEHAVIOR; ZINTEROL;
D O I
10.1007/BF02244339
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The purpose of the present study was to assess the behavioral effects of the beta adrenergic agonist zinterol and to determine whether its actions were mediated by beta adrenergic receptors. Zinterol reduced response rate and increased reinforcement rate of rats under a differential-reinforcement-of-low-rate schedule in a dose-dependent manner; significant decreases in response rate and increases in reinforcement rate were observed at doses of 0.1-1 mg/kg. The effect of 0.3 mg/kg zinterol on this behavior was blocked by pretreatment with the beta adrenergic antagonist propranolol. Zinterol also reduced locomotor activity in a dose-dependent manner; significant reductions were observed at doses of 0.3-10 mg/kg. Similarly, the effect of 1 mg/kg zinterol on locomotor activity was antagonized by propranolol. These effects of zinterol were similar to those of other beta adrenergic agonists as well as those of antidepressant drugs. Although the site of action (central versus peripheral) of zinterol was not determined in the present study, an experiment was carried out to determine if zinterol could act centrally after peripheral administration. The ability of repeated, systemic administration of zinterol to reduce the density of beta adrenergic receptors in cerebral cortex and cerebellum was determined. Repeated treatment with a high dose of zinterol (10 mg/kg, IP) reduced the density of beta adrenergic receptors in these brain regions, suggesting that, at least under certain conditions, systemically administered zinterol did have access to the central nervous system.
引用
收藏
页码:89 / 94
页数:6
相关论文
共 32 条
[1]  
[Anonymous], 1971, STAT PRINCIPLES EXPT
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]  
CONWAY PG, 1987, J PHARMACOL EXP THER, V241, P755
[4]  
DRAPER NR, 1981, APPLIED REGRESSION A
[5]  
ENNA SJ, 1981, ANTIDEPRESSANTS NEUR
[6]   A COMPARISON OF THE NEUROCHEMICAL AND BEHAVIORAL-EFFECTS OF CLENBUTEROL AND DESIPRAMINE [J].
FINNEGAN, KT ;
TERWILLIGER, MM ;
BERGER, PA ;
HOLLISTER, LE ;
CSERNANSKY, JG .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 134 (02) :131-136
[7]   PSYCHOPHARMACOLOGICAL PROFILE OF CLENBUTEROL [J].
FRANCES, H ;
PONCELET, M ;
DANTI, S ;
GOLDSCHMIDT, P ;
SIMON, P .
DRUG DEVELOPMENT RESEARCH, 1983, 3 (04) :349-356
[8]   PERIPHERAL MEDIATION OF EFFECTS OF CLENBUTEROL ON LOCOMOTOR AND INVESTIGATORY BEHAVIOR IN RATS [J].
GEYER, MA ;
FRAMPTON, SF .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1988, 30 (02) :417-420
[9]   ANTIDEPRESSANT-LIKE EFFECTS OF TRAZODONE ON A BEHAVIORAL SCREEN ARE MEDIATED BY TRAZODONE, NOT THE METABOLITE M-CHLOROPHENYLPIPERAZINE [J].
LI, AA ;
MAREK, GJ ;
HAND, TH ;
SEIDEN, LS .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 177 (03) :137-144
[10]  
MAREK GJ, 1988, PSYCHOPHARMACOLOGY, V96, P153